Table 4.
Distribution of IDH/TP53 mutation status and ATRX loss of expression in tumors of patients from the UCSF Adult Glioma Study
| IDH mutated cases with both ATRX and TP53 data available (n = 123) | ||||
| ATRX | TP53 | N | Percent | Fisher Exact test p-value |
| Intact | Wild type | 51 | 41.5% | <0.0001* |
| Intact | Mutated | 9 | 7.3% | |
| Lost | Wild type | 21 | 17.1% | |
| Lost | Mutated | 42 | 34.1% | |
| Total | 123 | |||
| Cases with both IDH and ATRX data available (N=259) | ||||
| IDH | ATRX | N | Percent | Fisher’s Exact test p-value |
| Wild type | Intact | 47 | 18.1% | 0.0017* |
| Wild type | Lost | 14 | 5.4% | |
| Mutated | Intact | 108 | 41.7% | |
| Mutated | Lost | 90 | 34.7% | |
| Total | 259 | |||
| Cases with both IDH and ATRX data available (stratified by 1p19q status) 1p19q codeleted (N=87) | ||||
| IDH | ATRX | N | Percent | Fisher’s Exact test p-value |
| Wild type | Intact | 5 | 5.7% | 0.3 |
| Wild type | Lost | 1 | 1.1% | |
| Mutated | Intact | 78 | 89.7% | |
| Mutated | Lost | 3 | 3.4% | |
| Total | 87 | |||
| 1p19q intact (N=63) | ||||
| IDH | ATRX | N | Percent | Fisher’s Exact test p-value |
| Wild type | Intact | 16 | 25.4% | 0.0004* |
| Wild type | Lost | 7 | 11.1% | |
| Mutated | Intact | 9 | 14.3% | |
| Mutated | Lost | 31 | 49.2% | |
| Total | 63 | |||
| 1p19q not assayed (tumors histologically classified as astrocytoma; N=101) | ||||
| IDH | ATRX | N | Percent | Fisher’s Exact test p-value |
| Wild type | Intact | 26 | 25.7% | <0.0001* |
| Wild type | Lost | 6 | 5.9% | |
| Mutated | Intact | 17 | 16.8% | |
| Mutated | Lost | 52 | 51.5% | |
| Total | 101 | |||
*
Statistical significance at the 0.05 level.